174 related articles for article (PubMed ID: 25326841)
1. [Extrapancreatic effects of GLP-1 receptor agonists: an open window towards new treatment goals in type 2 diabetes].
Salvador J; Andrada P
Med Clin (Barc); 2014; 143 Suppl 2():28-34. PubMed ID: 25326841
[TBL] [Abstract][Full Text] [Related]
2. [Extrapancreatic effects of GLP-1 receptor agonists: an open window towards new treatment goals in type 2 diabetes].
Salvador J; Andrada P
Med Clin (Barc); 2014 Sep; 143 Suppl 2():28-34. PubMed ID: 25437463
[TBL] [Abstract][Full Text] [Related]
3. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
Seufert J; Gallwitz B
Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
[TBL] [Abstract][Full Text] [Related]
4. [Effects of GLP-1 receptor agonists on carbohydrate metabolism control].
Fernández-García JC; Colomo N; Tinahones FJ
Med Clin (Barc); 2014; 143 Suppl 2():18-22. PubMed ID: 25326839
[TBL] [Abstract][Full Text] [Related]
5. GLP-1R as a Target for the Treatment of Diabetic Retinopathy: Friend or Foe?
Simó R; Hernández C
Diabetes; 2017 Jun; 66(6):1453-1460. PubMed ID: 28533296
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
7. GLP-1 Receptor Agonists and Cardiovascular Disease in Patients with Type 2 Diabetes.
Del Olmo-Garcia MI; Merino-Torres JF
J Diabetes Res; 2018; 2018():4020492. PubMed ID: 29805980
[TBL] [Abstract][Full Text] [Related]
8. GLP-1 receptor agonists and reduction of cardiometabolic risk: Potential underlying mechanisms.
Rizzo M; Nikolic D; Patti AM; Mannina C; Montalto G; McAdams BS; Rizvi AA; Cosentino F
Biochim Biophys Acta Mol Basis Dis; 2018 Sep; 1864(9 Pt B):2814-2821. PubMed ID: 29778663
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes and long-term complications: FOCUS on retinopathy.
Marchand L; Luyton C; Bernard A
Diabet Med; 2021 Jan; 38(1):e14390. PubMed ID: 32799379
[No Abstract] [Full Text] [Related]
10. Microvascular effects of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized controlled trials.
Dicembrini I; Nreu B; Scatena A; Andreozzi F; Sesti G; Mannucci E; Monami M
Acta Diabetol; 2017 Oct; 54(10):933-941. PubMed ID: 28748377
[TBL] [Abstract][Full Text] [Related]
11. GLP-1 Receptor Agonists in Diabetic Kidney Disease.
Michos ED; Tuttle KR
Clin J Am Soc Nephrol; 2021 Oct; 16(10):1578-1580. PubMed ID: 33849933
[No Abstract] [Full Text] [Related]
12. Cardiovascular safety and benefits of GLP-1 receptor agonists.
Dalsgaard NB; Brønden A; Vilsbøll T; Knop FK
Expert Opin Drug Saf; 2017 Mar; 16(3):351-363. PubMed ID: 28102093
[TBL] [Abstract][Full Text] [Related]
13. Pleiotropic effects of insulin and GLP-1 receptor agonists: Potential benefits of the association.
Cariou B
Diabetes Metab; 2015 Dec; 41(6 Suppl 1):6S28-6S35. PubMed ID: 26774017
[TBL] [Abstract][Full Text] [Related]
14. Topical Administration of GLP-1 Receptor Agonists Prevents Retinal Neurodegeneration in Experimental Diabetes.
Hernández C; Bogdanov P; Corraliza L; García-Ramírez M; Solà-Adell C; Arranz JA; Arroba AI; Valverde AM; Simó R
Diabetes; 2016 Jan; 65(1):172-87. PubMed ID: 26384381
[TBL] [Abstract][Full Text] [Related]
15. The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes.
Thomas MC
Diabetes Metab; 2017 Apr; 43 Suppl 1():2S20-2S27. PubMed ID: 28431667
[TBL] [Abstract][Full Text] [Related]
16. [Characteristics and types of GLP-1 receptor agonists. An opportunity for individualized therapy].
Jódar E
Med Clin (Barc); 2014; 143 Suppl 2():12-7. PubMed ID: 25326838
[TBL] [Abstract][Full Text] [Related]
17. Diabetic nephropathy: Renoprotective effects of GLP1R agonists and SGLT2 inhibitors.
Hocher B; Tsuprykov O
Nat Rev Nephrol; 2017 Dec; 13(12):728-730. PubMed ID: 28989173
[No Abstract] [Full Text] [Related]
18. GLP-1 receptor agonists: effects on cardiovascular risk reduction.
Lorber D
Cardiovasc Ther; 2013 Aug; 31(4):238-49. PubMed ID: 23865382
[TBL] [Abstract][Full Text] [Related]
19. [Results of the LEADER study: current evidence and perspectives in research].
Mannucci E
G Ital Cardiol (Rome); 2016 Dec; 17(12 Suppl 2):28S-31. PubMed ID: 28151519
[TBL] [Abstract][Full Text] [Related]
20. Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study.
Gaborit B; Julla JB; Besbes S; Proust M; Vincentelli C; Alos B; Ancel P; Alzaid F; Garcia R; Mailly P; Sabatier F; Righini M; Gascon P; Matonti F; Houssays M; Goumidi L; Vignaud L; Guillonneau X; Erginay A; Dupas B; Marie-Louise J; Autié M; Vidal-Trecan T; Riveline JP; Venteclef N; Massin P; Muller L; Dutour A; Gautier JF; Germain S
J Clin Endocrinol Metab; 2020 Apr; 105(4):. PubMed ID: 31589290
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
